Concerns raised last year over drug price deal delay

Exchequer unlikely to see any reprieve on prices until second half of 2016

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
20th March, 2016
Robert Watt, secretary general at the Department of Public Expenditure Pic:

The Department of Public Expenditure and Reform flagged concerns about delays in progressing a medicine price deal with big pharma a year ago.

The existing price deal that governs prices for the HSE’s €2 billion-plus spend on medicines was negotiated in 2012. With formal negotiations on a new deal yet to start, the exchequer is unlikely to see any reprieve on prices until the second half of 2016.

In a letter obtained under the Freedom...

Subscribe from just €1 for the first month!


What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Comment: Our reserves were not built to survive long Covid

Health Sarah O'Connor 2 hours ago

Design for Life: My father refuses to get the Covid-19 vaccine

Health Siobhan Murray 16 hours ago

Susan O’Keeffe: We must put women’s healthcare out of reach of the Church for good

Health Susan O'Keeffe 2 days ago

Covid-19: India’s crisis brings vaccine access inequality into sharp focus

Health Rachel Lavin 6 days ago